NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Kollodis BioSciences, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience - Kollodis signs new Distribution Agreement for MAPTrix® ECM line of products in England
Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience

 

NewswireToday - /newswire/ - Malden, MA, United States, 2010/01/05 - Kollodis signs new Distribution Agreement for MAPTrix® ECM line of products in England.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Kollodis BioSciences, Inc. announced today that it has entered into an Exclusive Distribution Agreement with Cambridge Bioscience Ltd. for the distribution of Kollodis BioSciences, Inc.'s MAPTrix® ECM line of products for cell culture and related applications. The exclusive agreement provides Cambridge Bioscience with the rights to distribute Kollodis’ cell culture products in the United Kingdom and Republic of Ireland.

Cambridge Bioscience is a well established marketing partner for life science technology companies wishing to build their business in the European markets. The initial term of the appointment is two years which may be extended.

Dr. Louis M. Scarmoutzos, President & CEO of Kollodis BioSciences, Inc., stated, "MAPTrix® is an exciting business opportunity providing a unique offering that can be of great value for its clients and customers in academics and in the pharmaceutical and life sciences industries. The appointment of Cambridge Bioscience as our distributor will provide us with an extended reach into the important UK and Ireland markets."

Mike Kerins, Managing Director at Cambridge Bioscience commented, “We are delighted to be working with Kollodis on the commercialization of their highly innovative MAPTrix® technology. We see wide application for this technology in the areas of stem cell research and tissue engineering.

Among the Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.

A MAPTrix® surface coating application promotes cell plating efficiency, improves morphology, and enhances cell proliferation under serum-free conditions in primary cell cultures such as hepatocytes or neural cells.

About Cambridge Bioscience Ltd

Cambridge Bioscience Ltd. is a leading distributor in the U.K. and Ireland, providing products for life science research. One of the longest established companies serving this market, Cambridge Bioscience has built a comprehensive product portfolio representing some of the world’s most innovative suppliers. With over 22 years of experience, the expertise and knowledge within the company is used in identifying and fulfilling the requirements of the research community. Additional information is available on the Company's website.

About Kollodis BioSciences, Inc.

Kollodis BioSciences, Inc. (kollodis.com) has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix® platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications. Additional information is available on the Company's website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Kollodis BioSciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sangjae Lee - Kollodis.com 
617-283-2182 lscarmoutzos[.]kollodis.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Kollodis BioSciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Kollodis BioSciences, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MONOVERSE USA, Inc.

Visit  The Franchise Group





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)